Adam JacksonJuly 29, 2022
AbbVie’s (NYSE:ABBV) stock slid 3% in early trading Friday despite posting positive second-quarter results — with news of an opioid settlement upward of $2 billion biting the biopharmaceutical giant this week. The company announced its financial results for the second quarter ending June 30, 2022. AbbVie posted $924 million in net earnings, with diluted EPS […]
